As reported by the Manila Times, the FDA has formally accepted uniQure’s biologics license application for ifezuntirgene inilparvovec (AMT-130), an experimental gene therapy being developed for people living with Huntington’s disease. The agency also granted the submission Priority Review, shortening the standard review timeline and setting a target decision date of May 1, 2027.
Should the therapy receive approval, it would become the first treatment aimed at slowing or modifying the disease process in Huntington’s disease, a rare, inherited neurodegenerative disorder for which no disease-modifying therapies are currently available.
FDA Review Moves Forward
The application was submitted through the FDA’s Accelerated Approval pathway, which allows earlier consideration of therapies for serious conditions based on evidence that suggests meaningful clinical benefit.
In its acceptance notice, the FDA indicated that an advisory committee meeting may be convened during the review process. Additional details regarding the timing of that meeting are expected at a later date.
Application Supported by Long-Term Clinical Data
uniQure’s regulatory filing relies largely on findings from its ongoing Phase I/II clinical program. The company previously reported three-year follow-up data showing outcomes in treated patients compared with a matched external control group drawn from the Enroll-HD observational database.
The company believes these data support the therapy’s potential to alter the course of Huntington’s disease by targeting the underlying biology responsible for disease progression.
Confirmatory Trial Planned Under Accelerated Approval Framework
To further establish clinical benefit, uniQure plans to launch a post-submission confirmatory study that has been developed in collaboration with the FDA.
The trial is expected to enroll roughly 200 participants and will compare AMT-130 plus standard management against standard care alone. Participants will be randomized in a 2-to-1 allocation, favoring treatment. Researchers will evaluate Total Functional Capacity (TFC) at 36 months as the study’s primary outcome measure.
Patient screening is projected to begin in the United States before the end of 2026.
Multiple Expedited Development Designations
The investigational therapy has received several FDA programs designed to accelerate development and review of promising treatments for serious diseases. These include:
- Breakthrough Therapy designation
- Regenerative Medicine Advanced Therapy (RMAT) designation
- Fast Track designation
According to uniQure, AMT-130 was the first Huntington’s disease therapy to obtain both Breakthrough Therapy and RMAT status.
Mechanism of Action
AMT-130 is a one-time gene therapy that employs uniQure’s proprietary miQURE® platform. The treatment uses a microRNA-based approach to suppress production of the huntingtin protein by silencing the huntingtin gene, including targeting a potentially harmful exon 1 protein fragment associated with disease pathology.
Administration requires a highly specialized neurosurgical procedure. Using MRI guidance and convection-enhanced delivery techniques, clinicians infuse the therapy directly into the striatum, specifically the caudate and putamen regions of the brain.
Overview of the Clinical Program
Across multiple Phase I/II studies, 51 patients have received the investigational therapy.
The U.S. trial enrolled 26 participants who either underwent treatment or received a sham procedure, with several control-group patients later crossing over to active treatment. A separate open-label European study included 13 patients. Additional cohorts have examined the effects of combining treatment with immunosuppression and have explored use of the therapy in patients with smaller striatal volumes.
These studies continue to generate long-term safety and efficacy data as the FDA evaluates the application.
Looking Ahead
The FDA’s acceptance of the biologics license application marks a major regulatory step for AMT-130 and for the broader Huntington’s disease field. With Priority Review now underway and a decision anticipated in May 2027, researchers, clinicians, and patient advocates will be watching closely to see whether the gene therapy becomes the first approved treatment designed to address the disease’s underlying progression.
